Related Experiment Video
Updated: Dec 6, 2025
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
Recent Update of HDAC Inhibitors in Lymphoma
I-Chung Chen1, Bidyadhar Sethy1, Jing-Ping Liou1
1School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Abstract:
Modulating epigenetic modification has been recognized for over a decade as an effective therapeutic approach to cancer and many studies of histone deacetylase (HDAC), one of the best known epigenetic modulators, have been published. HDAC modulates cell proliferation and angiogenesis and plays an essential role in cell growth. Research shows that up-regulated HDACs are present in many cancer types and synthetic or natural HDAC inhibitors have been used to silence overregulated HDACs. Inhibiting HDACs may cause arrest of cell proliferation, angiogenesis reduction and cell apoptosis. Recent studies indicate that HDAC inhibitors can provide a therapeutic effect in various cancers, such as B-cell lymphoma, leukemia, multiple myeloma and some virus-associated cancers. Some evidence has demonstrated that HDAC inhibitors can increase the expression of immune-related molecules leading to accumulation of CD8 + T cells and causing unresponsive tumor cells to be recognized by the immune system, reducing tumor immunity. This may be a solution for the blockade of PD-1. Here, we review the emerging development of HDAC inhibitors in various cancer treatments and reduction of tumor immunity.
Insights
Histone deacetylase (HDAC) inhibitors are emerging as a promising cancer therapy by arresting cell proliferation and enhancing immune response. These epigenetic drugs offer new hope for treating various cancers and overcoming immune resistance.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Research
Background:
- Epigenetic modification, particularly involving histone deacetylases (HDACs), is a recognized therapeutic strategy for cancer.
- HDACs play crucial roles in cell proliferation, angiogenesis, and growth, and are often upregulated in various cancers.
Purpose of the Study:
- To review the development of HDAC inhibitors in cancer treatment.
- To explore the role of HDAC inhibitors in modulating tumor immunity and overcoming immune resistance.
Main Methods:
- Review of published studies on HDAC inhibitors in cancer.
- Analysis of HDAC inhibitor mechanisms, including effects on cell proliferation, apoptosis, and immune response.
Main Results:
- HDAC inhibitors can arrest cell proliferation, reduce angiogenesis, and induce apoptosis.
- These inhibitors have shown therapeutic effects in B-cell lymphoma, leukemia, multiple myeloma, and virus-associated cancers.
- HDAC inhibitors can enhance anti-tumor immunity by increasing CD8+ T cell accumulation and making tumors recognizable to the immune system, potentially overcoming PD-1 blockade.
Conclusions:
- HDAC inhibitors represent a significant advancement in cancer therapy.
- Their ability to modulate the tumor immune microenvironment offers a novel strategy for treating resistant cancers.
More Related Videos
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
09:11Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Related Concept Videos
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26FDA Approved Drugs: Changes to Approved Drugs